organization · Reporting owner
Fosun Pharma USA Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NATURES SUNSHINE PRODUCTS INC
Report date June 27, 2025 · Filed June 27, 2025
Jointly reported with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Section 16 reporting ended · disclosed 2025-06-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Fosun Pharma USA Inc. | 0 |
Reported balance
After 2025-06-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-06-27 · Sale · Disposed 2,854,607 · Balance 0 F1: The shares were sold pursuant to that certain Underwriting Agreement. dated June 25, 2025, among Fosun Pharma USA Inc., the Issuer, and the underwriter party thereto. F2: Fosun Pharma USA Inc. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. |
| Common StockSEC Table I · non-derivative | Indirectby Fosun Industrial Co., Limited | 64,167 |
Reported balance
Holding disclosure · report date 2025-06-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 64,167 F3: Fosun Industrial Co., Limited is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold pursuant to that certain Underwriting Agreement. dated June 25, 2025, among Fosun Pharma USA Inc., the Issuer, and the underwriter party thereto.
F2: Fosun Pharma USA Inc. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
F3: Fosun Industrial Co., Limited is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 27, 2025 Filed Jun 27, 2025 20:27 UTC | NATURES SUNSHINE PRODUCTS INC NATR · Entity 1465 | SaleCommon Stock | 2,854,607 | $11.46 | $32,713,796.22 |
DisclosureSEC source: 0001140361-25-023976 · form4.xml · nonDerivative · entry 1 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. · CIK 0001615258 · 10% owner Fosun Pharma USA Inc. · CIK 0002071437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · by Fosun Pharma USA Inc. Disclosed balance after: 0 F1 · kind: The shares were sold pursuant to that certain Underwriting Agreement. dated June 25, 2025, among Fosun Pharma USA Inc., the Issuer, and the underwriter party thereto. F2 · ownership.nature: Fosun Pharma USA Inc. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.